Macrophage-targeted oligonucleotide therapeutics to downregulate inflammatory cytokines in non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) is thought the be the most common chronic liver disease in the world, affecting roughly a quarter of the global population. NAFLD describes a continuum of liver disease which is defined by the presence of liver steatosis, inflammation...
Published: |
|
---|---|
Online Access: | http://hdl.handle.net/2047/D20416550 |
Similar Items
-
Therapeutic approaches for non-alcoholic steatohepatitis
by: Luc F. Van Gaal, et al.
Published: (2021-09-01) -
Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
by: Shinji Takai, et al.
Published: (2020-10-01) -
Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
by: Abolghasem Hadinia, et al.
Published: (2019-12-01) -
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
by: Erik J. Tillman, et al.
Published: (2020-12-01) -
Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
by: Rasoul Akbari, et al.
Published: (2021-10-01)